Systemic Juvenile Idiopathic Arthritis (SJIA) patients constitute about 10% of all JIA population and represent the most distinct subtype of childhood arthritis. Most peripheral blood gene expression signatures that distinguish SJIA from other JIA subtypes reflect activation of the innate immune pathways in monomyelocytoid cells. A perplexing feature of SJIA is a strong association with macrophage activation syndrome (MAS), a life-threatening condition characterized by an overwhelming inflammatory reaction driven by excessive activation and expansion of T cells and hemophagocytic macrophages. While overt MAS is relatively rare, mild subclinical MAS may be occurring in 30-50% of patients with active SJIA. Our gene expression studies suggest that these patients can be distinguished by a gene expression pattern that combines a strong signature of erythropoiesis (most likely reflecting an increased red blood cell turnover in response to subclinical hemophagocytosis) and a strong signature of the alternative pathway of macrophage differentiation. Given the highly inflammatory nature of SJIA and the presence of IFN-y, a cytokine that normally drives the classic pro-inflammatory pathway of macrophage differentiation (Ml), the absence of the IFN-induced signature and emergence of the features of alternatively activated M2 macrophages in this setting are surprising. Preliminary evidence suggests that macrophages in SJIA may show altered responsiveness to IFN-y skewing their differentiation towards the M2 pathway. As a result, these macrophages may have a unique phenotype that does not fit the M1/M2 paradigm. Since hemophagocytic macrophages in MAS strongly express GDI 63, an M2 marker, we hypothesize that the pathways associated with skewing towards the M2 pathway of macrophage differentiation may also contribute to predisposition to MAS in SJIA. To explore this further first we will confirm that the presence of a strong signature of the alternative pathway of macrophage differentiation indeed identifies patients who are more likely to develop MAS (Sp.
Aim 1). We will then further characterize the phenotype of circulating monocytes/macrophages in SJIA in terms of M1/M2 polarization (Sp.
Aim 2). Finally, in Specific Aim 3, we will determine the phenotype of the macrophages in the bone marrow in pre-clinical and full blown MAS and assess the extent of it's overlap with the phenotype of circulating monocytes/macrophages in active SJIA as determined in Sp.
Aim 2. The long-term goal of this project is to identify pathways responsible for the development of MAS predisposition in SJIA and develop biomarkers for early diagnosis of this life-threatening condition.

Public Health Relevance

Macrophage Activation Syndrome (MAS) is a life-threatening complication of Systemic Juvenile Idiopathic Arthritis (SJIA). In clinical practice, there is a strong need for biomarkers that would help with an early diagnosis of MAS. In the proposed study we will explore gene expression signatures that distinguish patients with MAS, identify pathways that put SJIA patients at risk for MAS and develop a list of potential biomarkers of this potentially fatal condition.

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAR1-HL)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Cincinnati Children's Hospital Medical Center
United States
Zip Code
Hinks, Anne; Marion, Miranda C; Cobb, Joanna et al. (2018) Brief Report: The Genetic Profile of Rheumatoid Factor-Positive Polyarticular Juvenile Idiopathic Arthritis Resembles That of Adult Rheumatoid Arthritis. Arthritis Rheumatol 70:957-962
Schulert, Grant S; Zhang, Mingce; Husami, Ammar et al. (2018) Brief Report: Novel UNC13D Intronic Variant Disrupting an NF-?B Enhancer in a Patient With Recurrent Macrophage Activation Syndrome and Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol 70:963-970
Gohar, Faekah; Anink, Janneke; Moncrieffe, Halima et al. (2018) S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis. J Rheumatol 45:547-554
McIntosh, Laura A; Marion, Miranda C; Sudman, Marc et al. (2017) Genome-Wide Association Meta-Analysis Reveals Novel Juvenile Idiopathic Arthritis Susceptibility Loci. Arthritis Rheumatol 69:2222-2232
Langefeld, Carl D; Ainsworth, Hannah C; Cunninghame Graham, Deborah S et al. (2017) Transancestral mapping and genetic load in systemic lupus erythematosus. Nat Commun 8:16021
Moncrieffe, Halima; Bennett, Mark F; Tsoras, Monica et al. (2017) Transcriptional profiles of JIA patient blood with subsequent poor response to methotrexate. Rheumatology (Oxford) 56:1542-1551
Hinks, A; Bowes, J; Cobb, J et al. (2017) Fine-mapping the MHC locus in juvenile idiopathic arthritis (JIA) reveals genetic heterogeneity corresponding to distinct adult inflammatory arthritic diseases. Ann Rheum Dis 76:765-772
Ombrello, Michael J; Arthur, Victoria L; Remmers, Elaine F et al. (2017) Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications. Ann Rheum Dis 76:906-913
Prahalad, Sampath; McCracken, Courtney E; Ponder, Lori A et al. (2016) Familial autoimmunity in the Childhood Arthritis and Rheumatology Research Alliance registry. Pediatr Rheumatol Online J 14:14
Grom, Alexei A; Horne, AnnaCarin; De Benedetti, Fabrizio (2016) Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol 12:259-68

Showing the most recent 10 out of 56 publications